Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

DBCOND0055798Hematologic NeoplasmsNeoplasm by Histologic Type

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Classified under
Indicated drugs

What you can answer from here — as of October 22, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In